First‑Line Oral Antifungal Therapy for Tinea Capitis

Diagnosis and Immediate Treatment

• Obtain scalp specimens for microscopy and culture before starting therapy, but if a kerion or classic clinical signs (scaling, lymphadenopathy, alopecia) are present, begin oral antifungal treatment without delay 1.

Species‑Directed First‑Line Therapy

Trichophyton Species (e.g., T. tonsurans, T. violaceum, T. soudanense)

• Preferred agent: Terbinafine, because it provides superior efficacy and requires a shorter course (2–4 weeks) compared with other oral agents 1.
• Ineffective against Microsporum: Terbinahyde cannot be incorporated into hair shafts of pre‑pubertal children and does not reach scalp surface where arthroconidia reside, leading to treatment failure for Microsporum infections 1.

Terbinafine Dosing by Weight

All doses are oral and administered once daily 1.

Microsporum Species (e.g., M. canis, M. audouinii)

• Preferred agent: Griseofulvin, achieving an 88.5 % response rate for Microsporum infections 1.
• Licensing: It remains the only licensed oral treatment for pediatric tinea capitis in the United Kingdom; the suspension formulation is no longer licensed 1.
• Superiority: An 8‑week course of griseofulvin is significantly more effective than a 4‑week course of terbinafine for confirmed Microsporum infection 1.
• Potential drawback: The longer 6–8 week treatment duration may reduce patient compliance 1.

Griseofulvin Dosing by Weight

All doses are oral 1.

Management of Treatment Failure

• Systematically assess for: non‑compliance, suboptimal drug absorption, organism insensitivity, and reinfection from untreated contacts 1.
• If clinical improvement occurs but mycological tests remain positive: extend the current regimen for an additional 2–4 weeks 1.
• If no clinical improvement: switch immediately to a second‑line agent 1.

Second‑Line Therapy

• Preferred agent: Itraconazole, active against both Trichophyton and Microsporum species. Typical dosing is 5 mg kg⁻¹ day⁻¹ for 2–4 weeks or 50–100 mg day⁻¹ for 4 weeks 1.
• Alternative sequencing: If itraconazole was used first‑line, subsequent therapy should be terbinafine for Trichophyton infections or griseofulvin for Microsporum infections 1.
• Refractory cases: Fluconazole may be considered, although its use is limited by side‑effect profile and lack of cost advantage 1.

Defining Treatment Success

• Success is defined by mycological cure (negative microscopy/culture), not merely by clinical improvement 1.
• Repeat mycological sampling is required until clearance is documented 1.

Role of Topical Therapy

• Topical antifungals must not be used as monotherapy; they are only adjuncts to systemic treatment 1.

Contact Screening and Prevention

• Screen all household members and close contacts of cases caused by T. tonsurans and treat any positive individuals 1.
• Children receiving appropriate systemic therapy may continue attending school or nursery; exclusion is unnecessary once treatment has started 1.

Special Clinical Scenarios

• Asymptomatic carriers with a high spore burden (culture‑positive but no lesions) generally warrant systemic therapy 1.

Common Pitfalls to Avoid

• Do not discontinue therapy based solely on clinical appearance; continue until mycological cure is confirmed 1.
• Do not overlook household contacts; failure to screen and treat them leads to reinfection 1.

Treatment of Tinea Capitis in Children

Introduction to Treatment

• Oral antifungal therapy is required for tinea capitis in children, with the choice of medication determined by the causative dermatophyte species, with griseofulvin being the first-line treatment for Microsporum species and terbinafine for Trichophyton species 2, 3

Diagnosis

• Laboratory diagnosis should be obtained via scalp lesions sampling through scalpel scraping, hair pluck, brush, or swab, with specimens processed for microscopy and culture 2
• Treatment can be initiated while awaiting confirmatory mycology if a kerion is present or when cardinal clinical signs (scale, lymphadenopathy, alopecia) are evident 2

First-Line Treatment

• Griseofulvin remains the only licensed treatment for tinea capitis in children in the UK 2
• Griseofulvin dosing is as follows:
• Griseofulvin is more effective against Microsporum species (88.5% response rate) 3
• Terbinafine is more effective against Trichophyton species (T. tonsurans, T. violaceum, T. soudanense) 2
• Terbinafine requires a shorter treatment course (2-4 weeks), which may increase compliance 2
• Terbinafine dosing is as follows:
• Terbinafine is less effective against Microsporum species (67.9% response rate) 3

Second-Line Treatment

• Itraconazole is safe and effective with activity against both Trichophyton and Microsporum species 2
• Itraconazole dosing is as follows: 50-100 mg/day for 4 weeks, or 5 mg/kg/day for 2-4 weeks 2

Treatment Selection Algorithm

• Identify causative organism through laboratory diagnosis 2
• For Trichophyton species, first choice is Terbinafine (dosage based on weight) for 2-4 weeks 2
• For Microsporum species, first choice is Griseofulvin for 6-8 weeks 2

Treatment Failure Management

• Consider lack of compliance, suboptimal absorption, organism insensitivity, or reinfection 2
• If clinical improvement but ongoing positive mycology, continue current therapy for 2-4 more weeks 2
• If no clinical improvement, switch to second-line therapy 2
• For griseofulvin failure with Trichophyton, switch to terbinafine 2
• For terbinafine failure with Microsporum, switch to griseofulvin 2

Additional Measures

• Children receiving appropriate therapy can attend school or nursery 2
• Screen family members and close contacts for T. tonsurans cases and treat positive cases 2
• Clean contaminated combs and brushes with disinfectant 4

Monitoring and Follow-up

• Follow-up should include both clinical and mycological assessment until clearance is documented 4
• Mycological cure is the definitive endpoint for treatment, not just clinical response 4

Important Considerations

• Topical therapy alone is not recommended for tinea capitis; oral therapy is required for clinical and mycological cure 2
• The long treatment course required for griseofulvin may affect compliance 2
• Terbinafine appears well tolerated in children with side effects (gastrointestinal disturbances, rashes) in <8% of cases 3